Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Broadens License to Inpharmatica s PharmaCarta Platform

NEW YORK, Jan. 25 (GenomeWeb News) - Inpharmatica said today that it has expanded an informatics agreement with Pfizer that the companies initiated in 2000.

 

Under the expanded agreement, Pfizer will use four components of Inpharmatica's PharmaCarta technology platform. These components are in addition to Pfizer's current subscription to Biopendium, which the company first licensed five years ago.

 

Pfizer will gain access to Inpharmatica's StarLite database of curated medicinal chemistry information; to its DrugStore database of all known drugs, linked with their targets; and to the Admensa ADME prediction platform.

 

Inpharmatica will also use its proprietary PharmaCarta technology for a druggability assessment study.

 

Financial terms of the new agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.